- Home
- APXT vs CABA Comparison
APXT vs CABA Comparison
Compare APXT & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APXT | CABA |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.0M | 495.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | APXT | CABA |
|---|---|---|
| Price | $10.12 | $2.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 245.3K | ★ 4.6M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $1.26 |
| 52 Week High | $10.19 | $4.23 |
Technical Indicators
Market Signals| Indicator | APXT | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 61.37 | 43.02 |
| Support Level | N/A | $2.72 |
| Resistance Level | N/A | $3.34 |
| Average True Range (ATR) | 0.02 | 0.18 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 46.15 | 25.38 |
Price Performance
Historical ComparisonAbout APXT Apex Treasury Corporation Class A Ordinary Share
Apex Treasury Corp is a blank check company established for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.